
Medicine and Health
Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
M. Lapin, K. H. Edland, et al.
This study, conducted by Morten Lapin and colleagues at Stavanger University Hospital, explores the potential of circulating tumor DNA (ctDNA) as a prognostic marker in advanced pancreatic cancer. With improved prediction of clinical outcomes and a significant lead time in tracking disease progression, ctDNA presents a promising avenue for enhancing treatment monitoring.
Playback language: English
Related Publications
Explore these studies to deepen your understanding of the subject.